These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15655273)

  • 1. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
    Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
    Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    Ushiroyama T; Nosaka S; Ueki M
    Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
    Lai WT; Lee KT; Chu CS; Voon WC; Yen HW; Tsai LY; Sheu SH
    Int J Cardiol; 2005 Feb; 98(3):459-64. PubMed ID: 15708180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
    Kanbay M; Yildirir A; Bozbas H; Ulus T; Bilgi M; Muderrisoglu H; Akcay A; Ozdemir FN
    Ren Fail; 2005; 27(3):297-303. PubMed ID: 15957546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
    Seljeflot I; Tonstad S; Hjermann I; Arnesen H
    Thromb Res; 2002 Feb; 105(4):285-90. PubMed ID: 12031821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
    Sakabe K; Fukuda N; Wakayama K; Nada T; Shinohara H; Tamura Y
    Am J Cardiol; 2004 Aug; 94(4):497-500. PubMed ID: 15325939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.
    Matafome P; Monteiro P; Nunes E; Louro T; Amaral C; Moedas AR; Gonçalves L; Providência L; Seiça R
    Pharmacol Res; 2008; 58(3-4):208-14. PubMed ID: 18692137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
    Tehrani S; Mobarrez F; Antovic A; Santesson P; Lins PE; Adamson U; Henriksson P; Wallén NH; Jörneskog G
    Thromb Res; 2010 Sep; 126(3):e225-31. PubMed ID: 20637495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L; Parris W; Adeli K; Cheung RC
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
    Magnani G; Carinci V; Magelli C; Potena L; Reggiani LB; Branzi A
    J Heart Lung Transplant; 2000 Jul; 19(7):710-5. PubMed ID: 10930822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
    Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
    Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
    Trifiletti A; Lasco A; Scamardi R; Pizzoleo MA; Gaudio A; La Rocca R; Morini E; Frisina N
    Pathophysiol Haemost Thromb; 2003; 33(2):84-7. PubMed ID: 14624049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
    Okopien B; Huzarska M; Kulach A; Stachura-Kulach A; Madej A; Belowski D; Zielinski M; Herman ZS
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.